INTRODUCTION Many patients with coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, present with severe …

INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA
vaccines are highly effective at preventing infection and especially severe disease. However, …

mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their
efficacy in clinical trials, data on mRNA vaccine–induced immune responses are mostly limited …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced …

SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions
remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific …

Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and
the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …

Although critical illness has been associated with SARS-CoV-2–induced hyperinflammation,
the immune correlates of severe COVID-19 remain unclear. Here, we comprehensively …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within
the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been …

Importance Maternally derived antibodies are a key element of neonatal immunity. Understanding
the dynamics of maternal antibody responses to severe acute respiratory syndrome …

We examined antibody and memory B cell responses longitudinally for ∼9–10 months after
primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody …